MTR 0.00% $3.95 mantra group limited

Meditech Research

  1. 2,070 Posts.
    Seems the bonus of reduced heart damage in cancer patients is quite commercially significant.

    Continued pre-clinical testing of the Meditech Research Limited anti-cancer drug HyDOX(TM), has demonstrated that it substantially reduces heart damage that is often associated with doxorubicin
    chemotherapy. Breast and many other cancer patients are commonly treated with doxorubicin but prolonged treatment results In irreversible heart damage which reduces the amount of treatment a patient can tolerate with this efficacious, but toxic chemotherapy.
    Meditech Research has developed HyDOX(TM) a doxorubicin-hyaluronan combination using its patented HyACT(TM) platform technology. Prof Richard Fox of the Centre for Development of Cancer Therapeutics said
    "Earlier pre-clinical studies comparing HyDOX(TM) with doxorubicin alone clearly demonstrated that the Meditech product has superior anti-tumour capabilities so we are particularly encouraged that the reduction in cardiotoxicity seen in pre-clinical testing will be confirmed in human clinical trials. This could enable cancer patients to receive a treatment protocol with HyDOX(TM) that improves tumour response, substantially reduces associated toxicity, and offers the
    prospect of prolonged patient survival as well."

 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.